NCT04054752 2023-11-02Vaccine Response With NT-I7National Institutes of Health Clinical Center (CC)Phase 1 Withdrawn
NCT04065087 2022-03-17Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed GlioblastomaGenexine, Inc.Phase 1/2 Withdrawn